Patrys cancer antibody binds to two targets
22 April, 2013 by Dylan Bushell-EmblingLab studies into Patrys’s (ASX:PAB) cancer treatment candidate PAT-SM6 show that the antibody can bind to two separate targets.
AbbVie’s rheumatology tool proves popular
18 April, 2013A new web-based educational tool is engaging rheumatologists.
Professional development in therapeutics
13 April, 2013The ARCS Congress is coming up in Sydney at the beginning of June.
Sirtex completes recruitment for SIRFLOX study
12 April, 2013 by Dylan Bushell-EmblingSirtex Medical (ASX:SRX) has signed on the final patient for SIRFLOX, a trial of its SIR-Spheres liver cancer treatments that has been recruiting since 2006.
Taking breast cancer research into the clinic
12 April, 2013A team of Melbourne researchers has received funding to take their work on a new class of anticancer drugs out of the lab and into the clinic.
Patrys doses second group in myeloma trial
11 April, 2013 by Dylan Bushell-EmblingPatrys (ASX:PAB) has completed initial treatment for half of the 12 multiple myeloma patients to be involved in a clinical trial of anticancer antibody PAT-SM6.
Viralytics’ Cavatak well-tolerated intravenously
10 April, 2013 by Dylan Bushell-EmblingA phase I trial of intravenous delivery of Viralytics’ (ASX:VLA) Cavatak shows that the viral cancer treatment candidate was well tolerated.
Record funding for cancer research in the west
08 April, 2013The Cancer Council of Western Australia recently allocated $2.8 million in annual funding for research in Western Australia.
Philanthropy, advocacy and vision
03 April, 2013 by Susan WilliamsonResearch Australia has formed a collaborative international alliance with three advocacy groups.
Applications open for cancer research funding
03 April, 2013The 2013 round of funding from the Australian Cancer Research Foundation is now open.
Biolife breast cancer vaccine validated in journal
02 April, 2013The class of HER2/neu breast cancer vaccines to which Biolife Science’s HER-Vaxx belongs has been endorsed in a key breast cancer journal.
First Australian elected to Japanese Academy
27 March, 2013 by Susan WilliamsonProfessor Suzanne Cory is the first Australian to be admitted to the Japanese Academy of Science.
Cellmid close to royalties on cancer test licences
26 March, 2013 by Dylan Bushell-EmblingCellmid (ASX:CDY) has provided an update on the two cancer diagnostics tests under development by its licensees using midkines as a biomarker.
Viralytics CEO hails cancer virotherapy milestone
22 March, 2013 by Dylan Bushell-EmblingViralytics (ASX:VLA) CEO Dr Malcolm McColl has called the news that Amgen met its goal with an oncolytic virus trial a “milestone event for the field.”
Patrys cancer antibody synergistic in myeloma
21 March, 2013 by Dylan Bushell-EmblingAnimal trials of Patrys’s (ASX:PAB) anticancer antibody PAT-SM6 suggest the treatment is more effective when combined with other multiple myeloma treatments.
